C

    Cogent Biosciences Inc (COGT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $35.00
    +0.33 (+0.95%)

    Market Cap: $6.07B

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    35%(12/34)
    Avg Surprise
    -54.17%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.56
    Range$-0.61 - $-0.48
    7 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-0.57-2.6%
    60d ago$-0.57-2.4%
    30d ago$-0.57-2.4%
    7d ago$-0.57-2.6%
    Current$-0.56
    Revenue Consensus
    $666670
    Range$0 - $6M
    9 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.55
    Range$-0.88 - $-0.26
    9 analysts
    Revenue Consensus
    $5M
    Range$-666670 - $13M
    11 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.55---
    Sep 26EST
    		-$-0.56---
    Jun 26
    Reported Aug 4
    		$-0.52$-0.55+5.45%Beat+1.9%
    Mar 26
    Reported May 5
    		$-0.53$-0.50-5.66%Miss-1.0%
    Dec 25
    Reported Feb 17
    		$-0.56$-0.51-9.80%Miss-522.2%
    Sep 25
    Reported Nov 7
    		$-0.50$-0.52+3.85%Beat+21.9%
    Jun 25
    Reported Aug 5
    		$-0.53$-0.58+8.62%Beat+10.2%
    Mar 25
    Reported May 6
    		$-0.52$-0.58+9.05%Beat+15.3%
    Dec 24
    Reported Feb 25
    		$-0.09N/A+84.48%Beat+85.7%
    Sep 24
    Reported Nov 12
    		$-0.64$-0.57-12.28%Miss+0.0%
    Jun 24
    Reported Aug 6
    		$-0.59$-0.55-7.27%Miss+0.0%
    Mar 24
    Reported May 7
    		$-0.62$-0.51-21.57%Miss-8.8%
    Dec 23
    Reported Feb 26
    		$-0.63$-0.56-12.50%Miss-12.5%
    Sep 23
    Reported Nov 2
    		$-0.64$-0.53-20.75%Miss-28.0%
    Jun 23
    Reported Aug 8
    		$-0.59$-0.46-28.26%Miss+16.9%
    Mar 23
    Reported May 9
    		$-0.57$-0.53-7.55%Miss+16.2%
    Dec 22
    Reported Mar 14
    		$-0.56$-0.52-7.69%Miss+6.7%
    Sep 22
    Reported Nov 14
    		$-0.50$-0.52+3.85%Beat-4.2%
    Jun 22
    Reported Aug 9
    		$-0.71$-0.68-4.41%Miss-65.1%
    Mar 22
    Reported May 10
    		$-0.68$-0.49-38.78%Miss-100.0%
    Dec 21
    Reported Mar 15
    		$-0.60$-0.46-30.43%Miss+90.1%
    Sep 21
    Reported Nov 10
    		$-0.48$-0.38-26.32%Miss+52.9%
    Jun 21
    Reported Aug 16
    		$-0.43$-0.35-22.86%Miss+55.2%
    Mar 21
    Reported May 12
    		$-0.34$-0.22-54.55%Miss+57.5%
    Dec 20
    Reported Mar 16
    		$-6.06$-0.51-1088.24%Miss-2264.3%
    Sep 20
    Reported Nov 9
    		$-1.02$-0.14-628.57%Miss+34.6%
    Jun 20
    Reported Aug 11
    		$-0.96$-0.84-14.29%Miss+29.4%
    Mar 20
    Reported May 11
    		$-0.80$-1.23+34.96%Beat+48.7%
    Dec 19
    Reported Mar 26
    		$0.28N/A+124.56%Beat+124.1%
    Sep 19
    Reported Nov 12
    		$-1.56$-1.30-20.00%Miss-14.7%
    Jun 19
    Reported Aug 12
    		$-1.36$-1.60+15.00%Beat-9.7%
    Mar 19
    Reported May 13
    		$-1.56$-1.33-17.29%Miss-136.4%
    Dec 18
    Reported Mar 28
    		$-1.16$-1.41+17.73%Beat-383.3%
    Sep 18
    Reported Nov 12
    		$-1.36$-1.40+2.86%Beat-240.0%
    Jun 18
    Reported Aug 13
    		$-1.24$-1.38+10.14%Beat-113.8%
    Mar 18
    Reported May 14
    		$-0.66$-0.36-83.33%Miss-
    Dec 17
    Reported Mar 29
    		$-0.24$0.00N/AMiss-
    Sep 17
    Reported Nov 3
    		$-0.40$0.00N/AMiss-
    Mar 17
    Reported Jun 29
    		$-0.58$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-16.59EV/EBITDA-3.89x
    Price/FCF-19.35xFCF Yield-5.17%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-109.70%ROIC-52.47%
    Financial Health
    Debt/Equity0.00xInterest Coverage-82.94x
    Current Ratio13.57xQuick Ratio13.57x
    Trading Statistics
    Beta0.33Avg Volume1.83M
    52-Week High$43.7352-Week Low$11.60

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$36.28
    SMA 20$38.22
    SMA 50$38.66
    SMA 200$36.94
    EMA 10$36.42
    EMA 20$37.35
    EMA 50$37.69
    EMA 200$33.51

    MACD

    Line: -0.96Signal: -0.61Hist: -0.35

    ADX

    ADX: 25.1+DI: 12.3-DI: 29.6

    Aroon & PSAR

    Aroon Up24.0
    Aroon Down100.0
    PSAR$38.53

    Bollinger Bands

    Upper Band$43.38
    Lower Band$33.06
    %B Position2700%(Upper)
    Band Width0.19

    RSI (14-Day)

    Neutral
    38.7

    Momentum Oscillators

    Stoch %K16.7
    Stoch %D20.3
    Williams %R-82.9
    ROC (10d)-7.6%
    Momentum-2.87
    CCI (20d)-117.3
    MFI (14d)36.3

    Volatility Measures

    ATR (14d)$1.65(4.7%)
    StdDev (20d)2.58
    Hist Vol59.2%(High)

    Volume Flow

    VWAP$34.77
    OBV100.7M
    AD Line34.8M
    CMF (20d)0.054

    Volume Metrics

    Avg Vol (20d)1.8M
    Vol Ratio1.0x
    VWMA (20d)$38.64

    Pivot Points

    R3$38.48
    R2$37.66
    R1$36.17
    Pivot Point$35.35
    S1$33.85
    S2$33.03
    S3$31.54

    Advanced Oscillators

    TSI-14.61
    Ultimate Osc44.5
    KST-80.20

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total RevenueN/A$0$0$0$0$0$4.29M$0$0$0$5.59M$0
    Cost of RevenueN/A$1.16M$1.18MN/A$1.16M$1.14MN/A$1.10M$1.08M$1.07M$794,000$855,000
    Gross ProfitN/A$-1,155,000$-1,177,000N/A$-1,157,000$-1,138,000$2.15M$-1,097,000$-1,080,000$-1,066,000$4.79M$-855,000
    Operating Expenses$102.64M$102.45M$98.32M$83.36M$74.42M$74.93M$73.73M$75.41M$64.39M$62.40M$58.23M$59.58M
    R&D$70.81M$75.36M$74.38M$68.99M$61.05M$63.03M$62.05M$63.61M$54.29M$52.70M$48.72M$50.13M
    SG&A$31.83M$28.24M$23.93M$14.37M$13.38M$11.90M$11.69M$11.80M$10.09M$9.70M$9.51M$9.45M
    Operating Income$-102,638,000$-103,607,000$-99,493,000$-83,355,000$-75,582,000$-74,933,000$-73,734,000$-75,414,000$-64,387,000$-62,404,000$-58,228,000$-59,580,000
    Interest Income$0$7.61M$5.48M$3.89M$2.37M$2.95M$3.86M$4.78M$5.39M$4.06M$3.87M$4.20M
    Interest Expense$1.22M$1.21M$1.29M$1.46M$314,000$0$0$0$0$0$4.65M$0
    Income Before Tax$-96,405,000$-97,352,000$-102,492,000$-80,930,000$-73,529,000$-71,986,000$-67,927,000$-70,634,000$-58,950,000$-58,348,000$-54,365,000$-55,382,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$-4,057,000$-3,870,000$-855,000
    Net Income$-96,405,000$-97,352,000$-102,492,000$-80,930,000$-73,529,000$-71,986,000$-67,927,000$-70,634,000$-58,950,000$-58,348,000$-54,365,000$-55,382,000
    EBITDA$-94,447,000$-94,984,000$-104,603,000$-78,830,000$-72,058,000$-70,848,000$-66,819,000$-69,537,000$-57,870,000$-57,282,000$-53,571,000$-54,527,000
    EBIT$-95,188,000$-96,139,000$-105,744,000$-79,471,000$-73,215,000$-71,986,000$-67,927,000$-70,634,000$-58,950,000$-58,348,000$-54,365,000$-55,382,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about COGT

    News

    Cogent Biosciences director Arlene Morris sells $1.69m shares By Investing.com

    Cogent Biosciences director Arlene Morris sold approximately $1.69 million in company shares on August 27, 2026, through a pre-arranged trading plan, after exercising stock options on the same day. Despite the sale, analysts remain bullish on Cogent Biosciences, with price targets ranging from $45 to $62, citing positive clinical trial results for bezuclastinib and an upcoming FDA decision. The company's stock has shown impressive growth, up 189% over the past year, and it maintains strong liquid assets.

    Investing.com Australia•9/1/26•
    Somewhat-Bullish

    What Cogent Biosciences (COGT)'s Widening Net Losses Mean For Shareholders

    Cogent Biosciences reported widening net losses for Q2 and the half-year 2026, reaching US$96.41 million and US$193.76 million respectively, indicating increased investment in development. While these losses reinforce its pre-revenue, high-spend status, they don't change the near-term catalysts, such as upcoming FDA PDUFA dates for bezuclastinib. However, the higher cash burn raises concerns about financing conditions, potential dilution, and the company's ability to fund its pipeline, potentially affecting its valuation.

    Simply Wall Street•8/24/26•
    Somewhat-Bearish

    H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $55

    H.C. Wainwright has reiterated its Buy rating on Cogent Biosciences (COGT.US), maintaining a target price of $55. This continued positive outlook suggests confidence in the company's prospects.

    Moomoo•8/20/26•
    Bullish

    Has Cogent Biosciences (COGT) Run Too Far After Wider Losses?

    Cogent Biosciences (COGT) recently reported wider losses in Q2 2026, with a net loss of US$96.41 million. Despite a strong 213.21% total shareholder return over the past year, recent momentum has cooled, and the stock's high price-to-book ratio of 14.1x suggests a premium valuation, justified by its peer group but carrying risks related to clinical trials and ongoing losses. The article advises investors to consider the company's future execution and potential risks.

    Sahm•8/18/26•
    Somewhat-Bearish

    COGT Maintained by Piper Sandler -- Price Target Raised to $55

    Piper Sandler has maintained an "Overweight" rating for Cogent Biosciences (COGT) and raised its price target to $55.00, reflecting increased confidence in the company's potential, especially for its precision therapy program CGT9486. Despite this positive analyst outlook, Cogent Biosciences has a low GF Score™ of 30/100 and a high Price-to-Sales ratio of 220.78x, indicating potential overvaluation and challenges in profitability and growth, suggesting investors should proceed with caution.

    GuruFocus•8/17/26•
    Bullish

    Frequently Asked Questions About COGT

    Does COGT pay dividends?
    Cogent Biosciences Inc (COGT) does not currently pay a regular dividend.
    What is COGT's market cap?
    Cogent Biosciences Inc (COGT) has a market capitalization of $6.07B with a current stock price of $35.00.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In